Pages that link to "Q36612475"
Jump to navigation
Jump to search
The following pages link to High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up (Q36612475):
Displaying 50 items.
- Current issues facing the introduction of human papillomavirus vaccine in malaysia (Q34220545) (← links)
- The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis (Q34241823) (← links)
- Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine (Q34272071) (← links)
- Assessment of eight HPV vaccination programs implemented in lowest income countries (Q34279052) (← links)
- Effect of the decision-making process in the family on HPV vaccination rates among adolescents 9-17 years of age. (Q34291064) (← links)
- Tracking type specific prevalence of human papillomavirus in cervical pre-cancer: a novel sampling strategy (Q34304118) (← links)
- Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity (Q34352416) (← links)
- HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells (Q34395881) (← links)
- Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area (Q34512122) (← links)
- Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. (Q34549645) (← links)
- HPV knowledge in Mexican college students: implications for intervention programmes (Q34576328) (← links)
- Optimization of multimeric human papillomavirus L2 vaccines (Q34576677) (← links)
- Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review (Q34605012) (← links)
- HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection (Q34612818) (← links)
- Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia (Q34625933) (← links)
- Protecting our Khmer daughters: ghosts of the past, uncertain futures, and the human papillomavirus vaccine (Q34644634) (← links)
- Immune therapy for human papillomaviruses-related cancers (Q34657561) (← links)
- A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study (Q34701904) (← links)
- Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine (Q34729962) (← links)
- Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine (Q34730892) (← links)
- Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control. (Q34866621) (← links)
- Clinician's guide to human papillomavirus immunology: knowns and unknowns (Q34982885) (← links)
- Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer (Q35054754) (← links)
- Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection (Q35066537) (← links)
- Opportunities for increasing human papillomavirus vaccine provision in school health centers (Q35077462) (← links)
- The impact of HPV female immunization in Italy: model based predictions (Q35117850) (← links)
- Management strategies and cost effectiveness in the prevention of cervical cancer (Q35205476) (← links)
- Energetic changes caused by antigenic module insertion in a virus-like particle revealed by experiment and molecular dynamics simulations (Q35250141) (← links)
- Human papilloma virus vaccines: Current scenario (Q35366075) (← links)
- Efficacy of commercially available vaccines against HPV infection in women: a systematic review and meta-analysis (Q35427518) (← links)
- HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model (Q35498376) (← links)
- Prevalence of human papillomavirus infection in women in Benin, West Africa (Q35596164) (← links)
- HPV-induced anal lesions (Q35598917) (← links)
- A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection (Q35599310) (← links)
- How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? (Q35653703) (← links)
- Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization (Q35792707) (← links)
- The future of vaccines for cervical cancer (Q35805491) (← links)
- Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers (Q35812931) (← links)
- Human papillomavirus vaccine intent and uptake among female college students (Q35838751) (← links)
- Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa (Q35858737) (← links)
- Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial (Q35886534) (← links)
- Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study (Q35886612) (← links)
- Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results (Q35887140) (← links)
- The use of urine in the follow-up of HPV vaccine trials. (Q35887553) (← links)
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years (Q35918834) (← links)
- Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years (Q35918838) (← links)
- Human papillomavirus vaccines launch a new era in cervical cancer prevention (Q35944623) (← links)
- Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection (Q35944640) (← links)
- Prophylactic HPV vaccines (Q35984558) (← links)
- An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010 (Q36029073) (← links)